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Review criteria {#ijcp12924-sec-0006}
===============

This non‐systematic review identified recent clinical and epidemiological studies identified from PubMed/Medline and ClinicalTrials.gov from the US NIH and the Cochrane Register of Controlled Trials using the search terms bronchiectasis, non‐cystic fibrosis bronchiectasis, chronic pulmonary infection and computed tomography. Case reports, editorials and other communications with a low evidence level were excluded.

Message for the clinic {#ijcp12924-sec-0007}
======================

The prevalence of non‐cystic fibrosis bronchiectasis (NCFB) has increased over the past decades possibly due to increased awareness and widespread use of computed tomography (CT). NCFB should be suspected in patients with persistent cough, excessive sputum production and recurrent pulmonary infections. CT confirms the diagnosis with findings characterised by abnormally dilated airways, and is useful in determining the extent and severity of the disease and detecting an underlying cause.

1. Introduction {#ijcp12924-sec-0008}
===============

Bronchiectasis is a chronic, progressive respiratory disorder characterised by irreversibly and abnormally dilated airways, persistent cough, excessive sputum production and recurrent pulmonary infections.[1](#ijcp12924-bib-0001){ref-type="ref"} The changes in the bronchial walls may be due to chronic inflammation secondary to recurrent or chronic infections in the lung, but often the exact cause is not identified.[1](#ijcp12924-bib-0001){ref-type="ref"} Symptoms vary from intermittent episodes of respiratory infections with excessive mucus production to chronic symptoms with persistent daily expectoration of purulent sputum.[1](#ijcp12924-bib-0001){ref-type="ref"} In patients without cystic fibrosis, the condition is known as non‐cystic fibrosis bronchiectasis (NCFB).[1](#ijcp12924-bib-0001){ref-type="ref"}, [2](#ijcp12924-bib-0002){ref-type="ref"}, [3](#ijcp12924-bib-0003){ref-type="ref"} Although NCFB was once a very uncommon diagnosis, in the last two decades its prevalence has been increasing, making it more likely that primary care clinicians will encounter these patients in their practice. The precise prevalence of NCFB is difficult to determine because estimates vary among populations, but studies report a prevalence ranging from 486 to 1106 per 100 000 persons with an incidence that appears to be rising, particularly in women and older individuals.[4](#ijcp12924-bib-0004){ref-type="ref"}, [5](#ijcp12924-bib-0005){ref-type="ref"}, [6](#ijcp12924-bib-0006){ref-type="ref"} Although not as common as asthma, which affects approximately 10% of the world population, NCFB has become far more common than other respiratory conditions such as idiopathic pulmonary fibrosis, which affects only 18.2 per 100 000 persons.[7](#ijcp12924-bib-0007){ref-type="ref"}, [8](#ijcp12924-bib-0008){ref-type="ref"} Hospitalisation rates owing to NCFB have also increased in the United States, particularly in the older population.[9](#ijcp12924-bib-0009){ref-type="ref"}

Non‐cystic fibrosis bronchiectasis is associated with comorbidities such as anxiety, depression, fatigue, and has a significant impact on quality of life.[10](#ijcp12924-bib-0010){ref-type="ref"} Patients with NCFB require longer hospital stays and more outpatient visits compared with matched controls.[4](#ijcp12924-bib-0004){ref-type="ref"} Cough associated with NCFB can also impact the quality of life of family members.[10](#ijcp12924-bib-0010){ref-type="ref"} The effect of NCFB on mortality is not clear. Although reported mortality rates vary, evidence suggests that age‐adjusted mortality rates in patients with NCFB are at least twice that of the general population.[5](#ijcp12924-bib-0005){ref-type="ref"}

The increased recognition of NCFB is likely a result of the use of high‐resolution computed tomography (HRCT), which has allowed for the identification of previously undiagnosed disease.[11](#ijcp12924-bib-0011){ref-type="ref"}, [12](#ijcp12924-bib-0012){ref-type="ref"}, [13](#ijcp12924-bib-0013){ref-type="ref"} HRCT, which is able to acquire 1‐mm thick images of the lung at 10‐mm intervals, is considered the gold standard for radiographic diagnosis of NCFB.[1](#ijcp12924-bib-0001){ref-type="ref"}, [2](#ijcp12924-bib-0002){ref-type="ref"} Other modalities of CT using different imaging algorithms have been frequently used to effectively diagnose bronchiectasis.[12](#ijcp12924-bib-0012){ref-type="ref"}, [14](#ijcp12924-bib-0014){ref-type="ref"} With enhanced diagnostic capabilities of CT for NCFB, it is important for primary care clinicians to have an understanding of the information that can be obtained with this procedure. Herein, we review key radiographic findings on CT in the context of an overview of the pathophysiology, clinical presentation, and the diagnosis of NCFB.

2. Methods {#ijcp12924-sec-0009}
==========

For this review, trials and reports were identified from the databases of PubMed/Medline and ClinicalTrials.gov from the US NIH and the Cochrane Register of Controlled Trials. The search was carried out using the keywords or combinations of keywords: bronchiectasis, non‐cystic fibrosis bronchiectasis, chronic pulmonary infection and computed tomography. The term *chronic pulmonary infection* was included to capture the articles that discussed this condition in association with CT as a possible precursor of the development of NCFB. A particular emphasis was made on publications that discussed the epidemiology, natural history, clinical presentation and diagnosis. In addition, there was a focus on the available studies and publications that examined the role of CT in the diagnosis of bronchiectasis and determination of severity. No date or language restrictions were used.

3. Pathophysiology of NCFB {#ijcp12924-sec-0010}
==========================

Cole\'s 'vicious cycle' of infection, airway inflammation and lung damage[15](#ijcp12924-bib-0015){ref-type="ref"} is the most widely accepted mechanism of the development of NCFB (Figure [1](#ijcp12924-fig-0001){ref-type="fig"}). The cycle is triggered when the defence system of the lung is breached and mucociliary clearance is impaired. Potential causes of this breach include severe lower respiratory tract infections, gastric aspiration and/or inhalation of toxic gases. Other inflammatory processes may be associated with local and systemic inflammation that leads to changes in the architecture of bronchial airways. However, a clear trigger is not identified in up to 30%‐53% of patients.[1](#ijcp12924-bib-0001){ref-type="ref"} Regardless of the cause, when mucociliary clearance is impaired, mucous is retained in the airways.[15](#ijcp12924-bib-0015){ref-type="ref"} This in turn leads to microbial colonisation or infection with a subsequent development of an inflammatory response. As the host fails to eliminate the persistent infection, airway inflammation becomes chronic. Both host inflammatory responses and microbial cytotoxins cause additional structural damage to the lung and further impair mucus clearance, thus, the vicious cycle persists.[15](#ijcp12924-bib-0015){ref-type="ref"} Some microorganisms, such as *Pseudomonas aeruginosa*, may form biofilms in the bronchial airways. Biofilms are thin layers that form on colonised surfaces typically comprised of bacteria and a matrix of an extracellular polymeric substance that includes polysaccharides, proteins and DNA.[16](#ijcp12924-bib-0016){ref-type="ref"} This may facilitate the persistence of the "vicious cycle" of bronchiectasis because the biofilms protect bacteria from clearance by the host immune system and reduce the effects of antibiotics further potentiating airway inflammation.[17](#ijcp12924-bib-0017){ref-type="ref"} Disruption of the biofilms by some antibiotics (ie, macrolides) is thought to be one of the mechanisms by which chronic antibiotic therapy may improve outcomes in bronchiectasis.[18](#ijcp12924-bib-0018){ref-type="ref"}, [19](#ijcp12924-bib-0019){ref-type="ref"}

![Representation of the cycle that leads to development of bronchiectasis, as described by Cole[13](#ijcp12924-bib-0013){ref-type="ref"}](IJCP-71-na-g001){#ijcp12924-fig-0001}

3.1. Conditions Associated with the Development of NCFB {#ijcp12924-sec-0011}
-------------------------------------------------------

The various aetiologies of NCFB can be conceptually divided into infectious and non‐infectious causes. Previous severe infections from bacteria, mycobacteria and viruses have been shown to cause parenchymal changes consistent with NCFB. Non‐infectious causes include various types of immune deficiencies, conditions with defects in mucociliary clearance, bronchial obstruction, autoimmune diseases, congenital disorders, postradiation treatment, postlung transplant, interstitial lung diseases, and graft‐versus‐host disease. Table [1](#ijcp12924-tbl-0001){ref-type="table-wrap"} provides a comprehensive list of aetiologies.[1](#ijcp12924-bib-0001){ref-type="ref"}, [20](#ijcp12924-bib-0020){ref-type="ref"}

###### 

Conditions associated with the development of bronchiectasis[1](#ijcp12924-bib-0001){ref-type="ref"}, [14](#ijcp12924-bib-0014){ref-type="ref"}

  Categories                      Examples
  ------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Infections                      Bacterial (eg, Staphylococcus, Pseudomonas, Mycoplasma)Mycobacterial (eg, mycobacterium tuberculosis, MAC)Viral
  Immune deficiency               HypogammaglobulinemiaHIVIgG subclass deficiency
  Mucociliary clearance defects   PCDKartagener\'s syndromeCystic fibrosisYoung\'s syndrome (bronchiectasis, sinusitis, obstructive azoospermia)
  Bronchial obstruction           Endobronchial tumourBronchial compression by lymph nodeForeign bodyBroncholith
  Autoimmune disease              Sjögren\'s syndromeRheumatoid arthritisInflammatory bowel diseaseRelapsing polychondritisSystemic lupus erythematosus
  Congenital disorders            Bronchial atresiaα~1~‐antitrypsin deficiencyWilliams‐Campbell Syndrome (congenital deficiency of bronchial cartilage)Mounier‐Kuhn syndrome (congenital tracheobronchomegaly)Tracheal‐oesophageal fistulaYellow nail syndrome
  Other                           Allergic bronchopulmonary aspergillosisPostradiationPost‐transplantTraction bronchiectasisGraft‐versus‐host diseaseAssociated with COPD

COPD, chronic obstructive pulmonary disease; IgG, immunoglobulin G; MAC, mycobacterium avium complex; PCD, primary ciliary dyskinesia.
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3.2. The Association Between COPD and Bronchiectasis {#ijcp12924-sec-0012}
----------------------------------------------------

Chronic obstructive pulmonary disease (COPD) remains one of the most common pulmonary conditions worldwide, and patients with COPD are often seen in the primary care setting.[21](#ijcp12924-bib-0021){ref-type="ref"} Bronchiectasis and COPD often coexist with a varying prevalence amongst study populations (29%‐57%).[22](#ijcp12924-bib-0022){ref-type="ref"}, [23](#ijcp12924-bib-0023){ref-type="ref"}, [24](#ijcp12924-bib-0024){ref-type="ref"}, [25](#ijcp12924-bib-0025){ref-type="ref"} Both diseases share several pathophysiological features including increased airway inflammation, propensity for exacerbations, distortion of the architecture of the lung parenchyma and bacterial colonisation of the airways.

The presence of bronchiectasis identified on CT in patients with COPD has been associated with poor outcomes. A study by Martínez‐García demonstrated worse airflow limitation, increased isolation of potential pathogens, and more frequent hospital admissions in patients with COPD and bronchiectasis compared with patients with COPD alone.[24](#ijcp12924-bib-0024){ref-type="ref"} A follow‐up study from the same group showed that patients with bronchiectasis and COPD had an increased risk of all‐cause mortality.[26](#ijcp12924-bib-0026){ref-type="ref"} A meta‐analysis of 881 patients, including the above studies in addition to four others, revealed that the coexistence of COPD and bronchiectasis was associated with higher exacerbation rates, degree of inflammatory markers, and rates of *Pseudomonas aeruginosa* isolation.[27](#ijcp12924-bib-0027){ref-type="ref"} For these reasons, bronchiectasis is now considered a common comorbidity in patients with COPD.[21](#ijcp12924-bib-0021){ref-type="ref"} However, it is incompletely understood how these diseases exactly influence each other. The leading theory is that increased colonisation of the airways leads to increased inflammation, which in turn translates into increased risk for exacerbations.[28](#ijcp12924-bib-0028){ref-type="ref"} Future studies are needed to understand this complex association and to evaluate if identification of these patients early in their course may change outcomes.

4. Clinical Presentation {#ijcp12924-sec-0013}
========================

Non‐cystic fibrosis bronchiectasis presents with a range of clinical manifestations from incidentally found bronchiectasis in asymptomatic individuals to massive haemoptysis and respiratory failure. With the widespread use of CT, clinicians increasingly encounter the 'incidental' finding of bronchiectasis in asymptomatic patients who undergo chest or abdominal imaging for unrelated purposes. However, the most common clinical presentation is between these extremes.

For those patients with symptomatic bronchiectasis, the most common complaint is chronic cough. In fact, many patients have a chronic productive cough for over 30 years before their diagnosis. In one study of 103 adults with NCFB, 98% reported a chronic cough, while daily sputum production (typically purulent and averaging greater than 30 mL in volume) occurred in 76% of patients.[29](#ijcp12924-bib-0029){ref-type="ref"} Dyspnoea (62%) and chronic fatigue (74%) are also common presenting symptoms.[29](#ijcp12924-bib-0029){ref-type="ref"}, [30](#ijcp12924-bib-0030){ref-type="ref"} Other common characteristics in these patients include chronic rhinosinusitis that ranges from intermittent nasal discharge to severe purulent sinusitis (present in 70% of patients) and a notable history of ear, nose and throat surgery for recurrent sinusitis (30% of patients).[29](#ijcp12924-bib-0029){ref-type="ref"} Mild, intermittent haemoptysis occurs in 26%‐51% of cases, but at times it can be severe and life‐threatening.[29](#ijcp12924-bib-0029){ref-type="ref"}, [31](#ijcp12924-bib-0031){ref-type="ref"} Many patients with bronchiectasis require frequent hospital admissions for recurrent pneumonia.[29](#ijcp12924-bib-0029){ref-type="ref"}, [31](#ijcp12924-bib-0031){ref-type="ref"} Depression and anxiety are common in patients with bronchiectasis, which may significantly affect their quality of life.[32](#ijcp12924-bib-0032){ref-type="ref"}, [33](#ijcp12924-bib-0033){ref-type="ref"}

The natural history of NCFB is punctuated by periods of exacerbations, defined as acute worsening of respiratory symptoms that require management with antibiotic therapy.[34](#ijcp12924-bib-0034){ref-type="ref"} Patients with exacerbations experience change in one or more of the common symptoms of bronchiectasis, including increased sputum production or purulence, worsening cough and dyspnoea, and systemic symptoms.[1](#ijcp12924-bib-0001){ref-type="ref"} Usually, these episodes are triggered by a bronchial infection. In a study of 115 patients with NCFB, the most common signs of an acute exacerbation were increased frequency of cough (88%) and change in sputum characteristics (67%).[35](#ijcp12924-bib-0035){ref-type="ref"} Other symptoms included fever (28%), increase in sputum volume (42%) and increase in sputum purulence (35%).[35](#ijcp12924-bib-0035){ref-type="ref"} Exacerbations can range from a mild increase in respiratory symptoms to life‐threatening haemoptysis and respiratory failure.[1](#ijcp12924-bib-0001){ref-type="ref"}

*When should bronchiectasis be suspected in the primary care setting?* The diagnosis should be suspected in patients with chronic cough (ie, \>6 weeks) with variable production of purulent sputum, with or without recurrent haemoptysis, and frequent respiratory infections that tend to resolve slowly or partially with or without an underlying condition such as COPD. In some instances, bronchiectasis may be suggested on chest radiographs. This constellation of signs and symptoms should prompt the primary care provider to consider evaluating the patient for bronchiectasis.

5. Diagnostic Approach {#ijcp12924-sec-0014}
======================

5.1. Initial investigations {#ijcp12924-sec-0015}
---------------------------

Physical exam and history may contribute to the diagnosis of bronchiectasis. The most common respiratory physical exam findings are crackles, occurring in up to 73% of patients.[29](#ijcp12924-bib-0029){ref-type="ref"}, [31](#ijcp12924-bib-0031){ref-type="ref"} Other common findings include rhonchi (44%) and wheezing (21%‐34%).[29](#ijcp12924-bib-0029){ref-type="ref"}, [31](#ijcp12924-bib-0031){ref-type="ref"} Clubbing of the digits is rare and occurs in 2%‐3% of cases.[29](#ijcp12924-bib-0029){ref-type="ref"}, [31](#ijcp12924-bib-0031){ref-type="ref"}

Standard chest radiograph (CXR) is typically the first tool used to evaluate a patient with chronic respiratory symptoms. However, bronchiectasis may not be obvious with this imaging modality and is usually only apparent in severe cases.[36](#ijcp12924-bib-0036){ref-type="ref"}, [37](#ijcp12924-bib-0037){ref-type="ref"} Studies show that CXRs have moderate sensitivity (88%) and somewhat poor specificity (74%) for the detection of bronchiectasis,[36](#ijcp12924-bib-0036){ref-type="ref"}, [37](#ijcp12924-bib-0037){ref-type="ref"} and therefore is considered inadequate for the diagnosis/quantification of bronchiectasis.[1](#ijcp12924-bib-0001){ref-type="ref"} Despite this, CXRs may have some utility in NCFB. On close inspection, multiple areas of bronchial wall dilation may be seen in patients with moderate to severe bronchiectasis. Furthermore, other radiographic signs of chronic lower airway infection may be present in patients with NCFB such as calcifications or infiltrates.

5.2. Computed tomography {#ijcp12924-sec-0016}
------------------------

High‐resolution computed tomography of the chest is the current gold standard for the diagnosis/confirmation of bronchiectasis. It has a sensitivity of 96% and a specificity of 93%.[13](#ijcp12924-bib-0013){ref-type="ref"} Nevertheless, HRCT has some limitations, including respiratory and cardiac pulsation artefacts, false‐negative reports due to missed focal areas of bronchiectasis between section‐planes, and misinterpretation of bronchial‐artery ratio measurements.[11](#ijcp12924-bib-0011){ref-type="ref"} These limitations have been partially addressed using alternative CT modalities using different imaging algorithms. For example, a retrospective study evaluated the efficacy of HRCTs with 1‐mm slices every 10 mm, compared with multi‐detector CTs (MDCT) with contiguous 1‐mm slices for the diagnosis of bronchiectasis.[12](#ijcp12924-bib-0012){ref-type="ref"} MDCT was found to be superior in assessing the presence, extent and severity of bronchiectasis compared with HRCT.[12](#ijcp12924-bib-0012){ref-type="ref"} These findings were further supported by a prospective study, showing that MDCT indeed had greater accuracy for the identification and exclusion of bronchiectasis compared with HRCT.[14](#ijcp12924-bib-0014){ref-type="ref"} Although the utility of MDCT appears to be equivalent or even superior to HRCT, the radiation dose is up to five times higher with MDCT.[38](#ijcp12924-bib-0038){ref-type="ref"} Because of this concern, the use of low‐dose volumetric CT has been explored for the diagnosis of bronchiectasis. One such study by Jung and colleagues demonstrated no significant difference in the diagnostic yield of bronchiectasis, showing similar image quality and radiation exposures compared with HRCT.[39](#ijcp12924-bib-0039){ref-type="ref"}

Despite these advances, regular volumetric CT is sufficient to make the diagnosis of NCFB. This imaging modality offers the same degree of accuracy for NCFB and may be more widely available.[40](#ijcp12924-bib-0040){ref-type="ref"} As imaging technology progresses, it is likely that newer tools will be developed to better assess the presence and severity of bronchiectasis. The development of automated image analysis is one exciting innovation that has the potential to advance this diagnostic area, making it easier to identify milder forms of the disease and to improve the reliability of the diagnosis.[41](#ijcp12924-bib-0041){ref-type="ref"}, [42](#ijcp12924-bib-0042){ref-type="ref"} By diagnosing patients with bronchiectasis earlier in their course, it would allow for earlier therapeutic intervention, with the potential to improve outcomes and alter the course of the disease.

The characteristic feature of NCFB demonstrated by CT is bronchial wall dilation with the luminal diameter greater than 1‐1.5 the size of the accompanying pulmonary artery branch. Other typical findings include absence of normal tapering of the bronchi, bronchial wall thickening, mucoid plugging of the airways and proximity of visible airways close to the pleura (\<1 cm).[1](#ijcp12924-bib-0001){ref-type="ref"}, [43](#ijcp12924-bib-0043){ref-type="ref"}

Bronchiectasis is classified by morphology. In *cylindrical* bronchiectasis, the bronchial walls are dilated, but maintain their cylindrical shape extending to the periphery of the lung (Figure [2](#ijcp12924-fig-0002){ref-type="fig"}A). The *varicose* type of bronchiectasis is characterised by airway dilation interspersed with areas of relative narrowing, resulting in a beaded appearance (Figure [2](#ijcp12924-fig-0002){ref-type="fig"}B). *Cystic* bronchiectasis represents the most advanced stage of airway remodelling, with the dilated airways appearing similar to cysts or analogous to grapes along a branch (Figure [2](#ijcp12924-fig-0002){ref-type="fig"}C).

![Images from chest CT illustrating bronchiectasis classification based on morphology: A and B, cylindrical bronchiectasis in a 63 year‐old man with rheumatoid arthritis; C, varicose bronchiectasis in a 49 year‐old man with Kartagener\'s syndrome (ciliary dyskinesia, chronic sinusitis and situs inversus); and D, cystic bronchiectasis in a 77 year‐old woman with a history of a left lower lobe pneumonia](IJCP-71-na-g002){#ijcp12924-fig-0002}

The differential diagnosis is often narrowed based on imaging characteristics. For example, if a localised area of bronchiectasis is confirmed on CT, then referral to a pulmonologist for a bronchoscopy is required to evaluate for a foreign body, an endobronchial lesion, or an area of extrinsic compression that could potentially explain the focal finding.[1](#ijcp12924-bib-0001){ref-type="ref"} A localised area of bronchiectasis is rarely caused by a systemic/diffuse condition. If the area of bronchiectasis is diffuse on CT imaging, the differential diagnosis is broader.

Features or abnormalities demonstrated by CT may provide clues to the underlying cause of bronchiectasis.[20](#ijcp12924-bib-0020){ref-type="ref"}, [44](#ijcp12924-bib-0044){ref-type="ref"} In allergic bronchopulmonary aspergillosis, mucoid impaction of the large airways appears as tubular opacities referred to as the "finger‐in‐glove" sign. Similar to allergic bronchopulmonary aspergillosis, patients with CF have upper‐lobe predominant disease and may have the "finger‐in‐glove" sign. In patients with a foreign body, tumour or extrinsic compression, the bronchiectasis is evident in a focal area as opposed to more diffuse disease in other systemic conditions/aetiologies. Certain infections also may have a characteristic presentation. For example, atypical mycobacteria may favour the right middle lobe and the lingula.[45](#ijcp12924-bib-0045){ref-type="ref"} Despite identification of these key features on CT and extensive testing, no underlying aetiology is found in a large proportion of patients with bronchiectasis.[46](#ijcp12924-bib-0046){ref-type="ref"} The prevalence of idiopathic bronchiectasis varies amongst cohorts (32%‐66%) likely owing to geographic variations, diagnostic algorithms and other determinants.[30](#ijcp12924-bib-0030){ref-type="ref"}, [47](#ijcp12924-bib-0047){ref-type="ref"}, [48](#ijcp12924-bib-0048){ref-type="ref"}, [49](#ijcp12924-bib-0049){ref-type="ref"}, [50](#ijcp12924-bib-0050){ref-type="ref"}, [51](#ijcp12924-bib-0051){ref-type="ref"}

Clinical symptoms, history of exacerbations and microbiological data are frequently used to stratify the severity of patients with NCFB; however, the incorporation of imaging abnormalities into these classifications may allow for a more complete picture of the impact of the disease.[52](#ijcp12924-bib-0052){ref-type="ref"}, [53](#ijcp12924-bib-0053){ref-type="ref"} Therefore, there is great interest in the evaluation of the extent and severity of bronchiectasis more objectively using CT.

A method to quantify the extent of the disease using CT was developed several decades ago.[54](#ijcp12924-bib-0054){ref-type="ref"} In this method, each lobe is scored by: (i) the number of segments involved, (ii) severity of bronchial dilation compared with the adjacent artery, (iii) bronchial wall thickening and (iv) morphological type of bronchiectasis.

While imaging may be useful in the objective determination of the extent of the disease, it may have limited value with regard to the prognosis of NCFB. Two comprehensive bronchiectasis indices have been created to address this limitation in hopes of better understanding the prognosis of patients with NCFB and improving treatment algorithms.[55](#ijcp12924-bib-0055){ref-type="ref"}, [56](#ijcp12924-bib-0056){ref-type="ref"} Both the Bronchiectasis Severity Index (BSI) and the FACED scores are effective tools that utilise multiple parameters, including extent of the disease based on CT, to predict future outcomes in patients with bronchiectasis.

5.3. Pulmonary function testing {#ijcp12924-sec-0017}
-------------------------------

Spirometry is frequently used to evaluate patients with respiratory symptoms. In bronchiectasis, the majority of patients present with mild to moderate airway obstruction, with a forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio less than 70, along with an FEV1 \>50% predicted.[29](#ijcp12924-bib-0029){ref-type="ref"}, [31](#ijcp12924-bib-0031){ref-type="ref"} Significant bronchodilator response (response of \>200 mL and 12% predicted in FEV1 and FVC after administration of β~2~ agonists [57](#ijcp12924-bib-0057){ref-type="ref"}) occurs in only 22% of patients with NCFB.[29](#ijcp12924-bib-0029){ref-type="ref"} Interestingly, patients with a significant bronchodilator response tend to have more severe obstruction and poorer lung function as recently reported by Guan and colleagues.[57](#ijcp12924-bib-0057){ref-type="ref"} More severe obstruction (ie, FEV1\<50% predicted) is also associated with a history of pseudomonas infection or colonisation, multi‐lobar involvement of disease, greater sputum volume, greater purulent sputum and those patients with at least four exacerbations over a 2‐year period.[58](#ijcp12924-bib-0058){ref-type="ref"} It is important to note that spirometry may not significantly differ between the stable and exacerbation states.[35](#ijcp12924-bib-0035){ref-type="ref"} Although one study showed a statistically significant decline of both FEV1 and FVC by 3% (*P*≤.01) between the stable and exacerbation states, this is unlikely to be clinically significant.[59](#ijcp12924-bib-0059){ref-type="ref"} Spirometry should be performed at least annually in patients with bronchiectasis to detect progression of the disease.[1](#ijcp12924-bib-0001){ref-type="ref"} Pulmonary function testing may help detect and determine the severity of other underlying conditions such as interstitial lung disease, asthma and pulmonary hypertension.

5.4. Microbiology {#ijcp12924-sec-0018}
-----------------

Sputum cultures should be obtained in all patients with bronchiectasis. The most common organisms initially isolated from the sputum of patients with NCFB are Gram‐negative bacteria including *Haemophilus influenzae* (47%), *P. aeruginosa* (12%) and *Moraxella catarrhalis* (8%).[60](#ijcp12924-bib-0060){ref-type="ref"} Over time, this microbiological distribution shifts slightly, with *Pseudomonas* increasing in frequency. Six years after diagnosis, the most commonly isolated organisms continue to be *H. influenzae* (40%), *P. aeruginosa* (18%) and *M. catarrhalis* (7%).[60](#ijcp12924-bib-0060){ref-type="ref"} Gram‐positive bacteria are rare. *Streptococcus pneumoniae* is isolated in 4% of samples and *Staphylococcus aureus* is found in 3% of samples.[60](#ijcp12924-bib-0060){ref-type="ref"}

Isolation of *P. aeruginosa* is particularly important clinically. Patients with *Pseudomonas* have more severe disease, more rapid decline in lung function, more frequent exacerbations and reduced quality of life.[60](#ijcp12924-bib-0060){ref-type="ref"}, [61](#ijcp12924-bib-0061){ref-type="ref"}, [62](#ijcp12924-bib-0062){ref-type="ref"}, [63](#ijcp12924-bib-0063){ref-type="ref"} Thus, these patients need to be followed more carefully and referred to a pulmonologist for consideration of more aggressive therapeutic options.[61](#ijcp12924-bib-0061){ref-type="ref"}

Non‐tuberculous mycobacteria (NTM) constitute another group of important microorganisms in patients with NCFB and account for 2%‐30% of pathogens isolated.[64](#ijcp12924-bib-0064){ref-type="ref"}, [65](#ijcp12924-bib-0065){ref-type="ref"}, [66](#ijcp12924-bib-0066){ref-type="ref"}, [67](#ijcp12924-bib-0067){ref-type="ref"} In patients with bronchiectasis, the incidence of lung infection with NTM has increased over the past decades.[68](#ijcp12924-bib-0068){ref-type="ref"}, [69](#ijcp12924-bib-0069){ref-type="ref"}, [70](#ijcp12924-bib-0070){ref-type="ref"} The most common NTM isolated in NCFB is *Mycobacaterium avium complex*.[65](#ijcp12924-bib-0065){ref-type="ref"}, [66](#ijcp12924-bib-0066){ref-type="ref"}, [67](#ijcp12924-bib-0067){ref-type="ref"} The diagnosis of NTM is particularly challenging in patients with NCFB because of existing abnormalities that may or may not be caused by NTM. Unlike *Mycobaterium tuberculosis*, NTM are harboured in the soil and water, and infection is acquired from these sources rather than person‐to‐person transmission. For these reasons, NTM isolated in the sputum may represent "contamination" or "colonization" but not necessarily infection. Consequently, the diagnosis of an NTM infection requires a careful evaluation of the clinical signs and symptoms, culture positivity and imaging abnormalities.[71](#ijcp12924-bib-0071){ref-type="ref"} Advanced age, low body‐mass index, female gender and low frequency of chronic *P. aeruginosa* infection have been independently linked to the presence of NTM in patients with NCFB.[65](#ijcp12924-bib-0065){ref-type="ref"}, [66](#ijcp12924-bib-0066){ref-type="ref"} The reasons for these observations are incompletely understood. In the primary care setting, when NTM is encountered in the sputum, repeat cultures should be obtained to further aid in the determination of the significance of these findings and refer the patient to a center that has experience in the treatment of these infections.

Patients with NCFB can become chronically colonised with bacteria that may result in recurrent episodes of pneumonia or exacerbations of bronchiectasis in the susceptible host.[1](#ijcp12924-bib-0001){ref-type="ref"}, [72](#ijcp12924-bib-0072){ref-type="ref"}, [73](#ijcp12924-bib-0073){ref-type="ref"} Dilated airways cause pooling of secretions in dependent regions of the lung, creating an ongoing reservoir for bacterial growth and re‐infection. Exacerbations may be characterised by an increased bacterial burden of these same organisms quantitatively, and not necessarily infection with a new organism.[1](#ijcp12924-bib-0001){ref-type="ref"} This is supported by observations that suggest that the lung microbiome remains stable during an exacerbation.[74](#ijcp12924-bib-0074){ref-type="ref"}

5.5. Laboratory investigations {#ijcp12924-sec-0019}
------------------------------

Once bronchiectasis is suspected based on clinical presentation and confirmed by radiographic imaging, determining the underlying cause is a key to effective therapeutic management. Initial laboratory tests should always include sputum culture, gram stain and three acid‐fast bacterial stains with culture to evaluate and treat an acute infectious process that may be ongoing.[1](#ijcp12924-bib-0001){ref-type="ref"} Microbiologic testing should be repeated in the patient presenting with worsening symptoms. There is no consensus on how often microbiologic testing should be performed in the "stable" patient, but experts advocate testing the sputum for pathogenic bacteria from every visit to every 6 months.[1](#ijcp12924-bib-0001){ref-type="ref"} Additional testing should include: a complete blood count, a chemistry panel (CHEM 10), liver function tests, an HIV screen, immunoglobulin panel, an alpha‐1 antitrypsin level, aspergillus serologies, serum protein electrophoresis, an erythrocyte sedimentation rate/C‐reactive protein level and a comprehensive autoimmune panel.[1](#ijcp12924-bib-0001){ref-type="ref"} These tests are recommended even in asymptomatic patients given that identifying an underlying cause of bronchiectasis may help establish therapy earlier and prevent the progression of the disease. More specific tests are required for patients with chronic sinus infections, those under the age of 40, or patients with symptoms of reflux. A diagnostic algorithm is shown in Figure [3](#ijcp12924-fig-0003){ref-type="fig"}.[1](#ijcp12924-bib-0001){ref-type="ref"}

![Algorithm outlining the diagnostic steps for determining the underlying cause of bronchiectasis in symptomatic adults. A1AT, α~1~‐antitrypsin; ABPA, allergic bronchopulmonary aspergillosis; AFB, acid‐fast bacilli; CBC, complete blood count; CCP, cyclic citrullinated peptide; CF, cystic fibrosis; CRP, C‐reactive protein; CVID, common variable immune deficiency; EGD, esophagogastroduodenoscopy; ESR, erythrocyte sedimentation rate; GERD, gastroesophageal reflux disease; GS, gram stain; IgG, immunoglobulin G; LFT, liver function test; NTM, nontuberculous mycobacteria; PCD, primary ciliary dyskinesia; RAST, radioallergosorbent test; RF, rheumatoid factor; SSA, Sjögren\'s syndrome A antibody; SSB, Sjogren\'s syndrome B antibody; UACS, Upper Airway Cough Syndrome](IJCP-71-na-g003){#ijcp12924-fig-0003}

5.6. When should primary care consult a specialist? {#ijcp12924-sec-0020}
---------------------------------------------------

Because bronchiectasis may be associated with progressive lung function decline and recurrent pulmonary infections, it is important for this disease to be recognised early so appropriate interventions can be instituted. The first step is to attempt to identify underlying causes of bronchiectasis (as discussed above and shown in Figure [3](#ijcp12924-fig-0003){ref-type="fig"}) and treat them when indicated. In the primary care setting, patients with bronchiectasis should be followed periodically for an assessment of their symptoms and lung function. A careful history of their respiratory symptoms, previous infections and imaging abnormalities should be documented. Patients with bronchiectasis should be referred to a respiratory specialist if they have haemoptysis, recurrent infections/exacerbations or a rapid decline in the exercise tolerance or pulmonary function testing.[1](#ijcp12924-bib-0001){ref-type="ref"}, [10](#ijcp12924-bib-0010){ref-type="ref"} Patients with bronchiectasis limited to one pulmonary lobe may require a referral to a pulmonologist for a bronchoscopy to evaluate for the presence of a local endobronchial obstruction or narrowing. A respiratory therapist should be consulted if the patient has production of copious secretions or evidence of mucus plugging on CT to establish airway clearance techniques (ACT).

After the underlying cause of bronchiectasis is treated (if identified), the goals of therapy should be directed towards disrupting the "vicious cycle". ACT may prevent mucous retention in the airways and have been shown to improve sputum expectoration, pulmonary function and quality of life.[75](#ijcp12924-bib-0075){ref-type="ref"} ACT in clinical practice comprise of various manoeuvres such as drainage assisted by gravity, breathing exercises, directed coughing ("huff‐cough"), expiratory oscillating devices (ie, Acapella^®^, Aerobika^®^) and positive expiratory pressure devices. Patient preference, tolerability and severity of the disease should be considered when respiratory therapists select the most appropriate ACT for a patient with bronchiectasis. In the primary care setting, once a specific type of ACT has been selected, the patients should be questioned about the regular use of this therapy and encouraged to be as compliant as possible. Chronic use of antibiotics, both oral and inhaled, has been used as suppressive therapy in selected patients with additional improvements in exacerbation rates, symptoms scores and quality of life markers.[76](#ijcp12924-bib-0076){ref-type="ref"}, [77](#ijcp12924-bib-0077){ref-type="ref"} These therapies should be carefully tailored based on the extent of the disease, daily symptoms and culture results.

6. Conclusion {#ijcp12924-sec-0021}
=============

The incidence of NCFB has risen over the past decades. The reasons for this increase is multifactorial and may be related to improved physician awareness, improved testing and widespread availability of CT. Other, more complex, explanations such as the rise in the incidence of infections, antibiotic resistance and increased incidence of autoimmune conditions likely play a part in the increased rate in which NCFB is encountered in clinical practice. The conditions associated with the development of NCFB are varied and the diagnostic workup should target these when clinically indicated. In the primary care setting, it is important to consider the diagnosis of bronchiectasis in patients with chronic respiratory symptoms that cannot be explained by another diagnosis. CT of the chest is the gold standard for the diagnosis of NCFB. In addition, this tool provides a wealth of information that may be used to identify an underlying condition and determine the extent and severity of the disease. With early and improved diagnosis of NCFB, it is more likely that therapeutic regimens will be effective and prevent the progression of the disease.
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